Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Belgium
  4. Euronext Bruxelles
  5. UCB
  6. News
  7. Summary
    UCB   BE0003739530

UCB

(UCB)
  Report
Real-time Euronext Bruxelles  -  11:35 2022-10-06 am EDT
73.18 EUR   +2.01%
09/27Ucb : FINTEPLA (fenfluramine) Approved in Japan for the Treatment of Seizures Associated with Dravet Syndrome
PU
09/23Ucb : Disposal of own shares
PU
09/22Ucb : presents latest data from generalized myasthenia gravis portfolio at AANEM meeting
PU
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

UCB : Transparency notification FMR LLC

08/05/2022 | 02:16pm EDT
Transparency notification FMR LLC

Brussels (Belgium), 5 August 2022 - 20:05 (CEST) - Regulated information

1. Summary of the notification

Pursuant to Article 14 of the law of 2 May 2007 on the disclosure of large shareholdings, UCB SA/NV announces that it received a transparency notification from FMR LLC. (having its registered office at The Corporation Trust Center, 1209 Orange Street, Wilmington, New Castle County, Delaware, 19801, U.S.A.) on 3 August 2022.

FMR LLC., notified that, following a disposal of UCB shares with voting rights by its affiliates, the shareholding in UCB SA/NV of a controlled entity decreased and crossed downwards the 3% threshold, on 1 August 2022.

On 1 August 2022, FMR LLC. (taking into account the holding of its affiliates) owned 7 509 016 UCB shares with voting rights, representing 3.86% of the total number of shares issued by the company (194 505 658), versus 4.99 % (9 698 901 UCB shares) in the previous notification dated 24 May 2022.

2. Content of the notification

  • Reason for the notification: Acquisition or disposal of voting securities or voting rights.
  • Notification by: A parent undertaking or a controlling person.
  • Persons subject to the notification requirement:
  • Date on which the threshold is crossed: 1 August 2022.
  • Threshold crossed (in %): 3%.
  • Denominator: 194 505 658.
  • Notified details:
  • Chain of controlled undertakings through which the holding is effectively held:

​​​​​​​​​​​​​​

  • Additional information: The holdings attributed to the entities mentioned in heading 10 arise from holdings of various undertakings for collective investment that are managed by FIAM LLC, Fidelity Institutional Asset Management Trust Company, Fidelity Management & Research Company LLC, Fidelity Management Trust Company, FMR Investment Management (UK) Limited and Strategic Advisers LLC each of which are entities that are subsidiaries of and controlled by FMR LLC. The entities mentioned in heading 10 are the discretionary investment managers and exercise the voting rights at their discretion in the absence of specific instructions. Threshold crossed by a Controlled Undertaking.

3. Further information

This press release and the detailed transparency notification are available on UCB SA/NV's website via the following link.

An updated overview of the UCB SA/NV large shareholdings will be available on UCB SA/NV's website via the following link.

For further information, contact UCB:

Investor Relation
Antje Witte
T +32 2 559 94 14
antje.witte@ucb.com

Corporate Communications
Laurent Schots
T+32 2 559 92 64
​​​​​​​laurent.schots@ucb.com

About UCB

UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With approximately 8 600 people in nearly 40 countries, the company generated revenue of € 5.8 billion in 2021. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Twitter: @UCB_news

Asset Download
2 Likes

Disclaimer

UCB SA published this content on 05 August 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 05 August 2022 18:15:12 UTC.


© Publicnow 2022
All news about UCB
09/27Ucb : FINTEPLA (fenfluramine) Approved in Japan for the Treatment of Seizures Associated w..
PU
09/23Ucb : Disposal of own shares
PU
09/22Ucb : presents latest data from generalized myasthenia gravis portfolio at AANEM meeting
PU
09/20Ucb : European Medicine Agency Accepts Marketing Authorization Applications for Bimekizuma..
PU
09/09Ucb : Disposal of own shares
PU
09/09Ucb : Financial Reporting Document
PU
09/09UCB : Share buyback
CO
09/07Ucb : Looking forward to an exceptional EADV 2022 experience
PU
09/07UCB Announces New Three-Year Results from the BE BRIGHT Open-Label Extension Study
CI
09/07Ucb : New Three-Year BIMZELX▼ (bimekizumab) Data Reinforce Long-Term Maintenance of ..
PU
More news
Analyst Recommendations on UCB
More recommendations
Financials
Sales 2022 5 352 M 5 276 M 5 276 M
Net income 2022 543 M 535 M 535 M
Net Debt 2022 2 410 M 2 376 M 2 376 M
P/E ratio 2022 25,7x
Yield 2022 1,88%
Capitalization 13 628 M 13 393 M 13 436 M
EV / Sales 2022 3,00x
EV / Sales 2023 2,91x
Nbr of Employees 8 600
Free-Float 59,6%
Chart UCB
Duration : Period :
UCB Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends UCB
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Last Close Price 71,74 €
Average target price 101,23 €
Spread / Average Target 41,1%
EPS Revisions
Managers and Directors
Jean-Christophe Tellier Chief Executive Officer & Executive Director
Sandrine Dufour Chief Financial Officer & Executive Vice President
Stefan Oschmann Chairman
Iris Löw-Friedrich Chief Medical Officer, EVP & Head-Development
Dhavalkumar Patel Chief Scientific Officer & Executive VP
Sector and Competitors
1st jan.Capi. (M$)
UCB-28.51%13 436
CSL LIMITED-0.08%90 424
SAMSUNG BIOLOGICS CO.,LTD.-10.63%40 403
BIOGEN INC.9.07%37 975
WUXI BIOLOGICS (CAYMAN) INC.-45.60%27 338
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.-30.63%19 439